TWEAK: A novel biomarker for lupus nephritis?

Arthritis Research and Therapy

Volumn 11, Issue 6, 2009, Pages

  Dhaun, Neeraj ^a   Kluth, David C ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS INDUCING FACTOR; BIOLOGICAL MARKER; CREATININE; CYTOKINE; ENDOTHELIN 1; HEPCIDIN; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PROTEIN TWEAK; UNCLASSIFIED DRUG; TNFSF12 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR;

CREATININE BLOOD LEVEL; DISEASE ACTIVITY; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; EDITORIAL; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; LUPUS ERYTHEMATOSUS NEPHRITIS; NEPHRITIS; PROTEIN BLOOD LEVEL; UPREGULATION; HUMAN; URINE;

BIOLOGICAL MARKERS; HUMANS; LUPUS NEPHRITIS; TUMOR NECROSIS FACTORS;

EID: 77952480478     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar2846     Document Type: Editorial

References (10)

1. Schwartz N, Rubinstein T, Burkly LC, Collins CE, Blanco I, Su L, Hojaili B, Mackay M, Aranow C, Stohl W, Rovin BH, Michaelson JS, Putterman C. Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study. Arthritis Res Ther 2009, 11:R143. 10.1186/ar2816, 19785730.
2. Seshan SV, Jennette JC. Renal disease in systemic lupus erythematosus with emphasis on classification of lupus glomerulonephritis: advances and implications. Arch Pathol Lab Med 2009, 133:233-248.
3. Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JW, Dadoniené J, Ekstrand A, Gaskin G, Gregorini G, de Groot K, Gross W, Hagen EC, Mirapeix E, Pettersson E, Siegert C, Sinico A, Tesar V, Westman K, Pusey C, . European Vasculitis Study Group A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003, 349:36-44. 10.1056/NEJMoa020286, 12840090, European Vasculitis Study Group.
4. Hewitt SM, Dear J, Star RA. Discovery of protein biomarkers for renal diseases. J Am Soc Nephrol 2004, 15:1677-1689. 10.1097/01.ASN.0000129114.92265.32, 15213255.
5. Winkles JA. The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting. Nat Rev Drug Discov 2008, 7:411-425. 10.1038/nrd2488, 18404150.
6. Zhao Z, Burkly LC, Campbell S, Schwartz N, Molano A, Choudhury A, Eisenberg RA, Michaelson JS, Putterman C. TWEAK/Fn14 interactions are instrumental in the pathogenesis of nephritis in the chronic graft-versus-host model of systemic lupus erythematosus. J Immunol 2007, 179:7949-7958.
7. Rovin BH, Song H, Birmingham DJ, Hebert LA, Yu CY, Nagaraja HN. Urine chemokines as biomarkers of human systemic lupus erythematosus activity. J Am Soc Nephrol 2005, 16:467-473. 10.1681/ASN.2004080658, 15601744.
8. Brunner HI, Mueller M, Rutherford C, Passo MH, Witte D, Grom A, Mishra J, Devarajan P. Urinary neutrophil gelatinase-associated lipocalin as a biomarker of nephritis in childhood-onset systemic lupus erythematosus. Arthritis Rheum 2006, 54:2577-2584. 10.1002/art.22008, 16868980.
9. Zhang X, Jin M, Wu H, Nadasdy T, Nadasdy G, Harris N, Green-Church K, Nagaraja H, Birmingham DJ, Yu CY, Hebert LA, Rovin BH. Biomarkers of lupus nephritis determined by serial urine proteomics. Kidney Int 2008, 74:799-807. 2614389, 18596723, 10.1038/ki.2008.316.
10. Dhaun N, Lilitkarntakul P, Macintyre IM, Muilwijk E, Johnston NR, Kluth DC, Webb DJ, Goddard J. Urinary endothelin-1 in chronic kidney disease and as a marker of disease activity in lupus nephritis. Am J Physiol Renal Physiol 2009, 296:F1477-1483. 10.1152/ajprenal.90713.2008, 19279127.